Bodyport · Nov 2024
Bodyport added Jim Pursley to its board as it described a move into commercialization and growth.
Predicting and preventing heart disease.
Company research
Public company, workplace, funding, and market signals
Overview
Bodyport is a San Francisco-based digital therapeutics company focused on heart-failure / fluid-management monitoring. Its core product is the FDA-cleared Bodyport Cardiac Scale plus Congestion Index software, which combines hemodynamic biomarkers, a clinical portal, and a patient app to support remote care. Public leadership data are partly stale: older company pages still refer to John Lipman as CEO, while his 2026 LinkedIn profile lists him as a current Bodyport board member after Nov. 2025.
Primary product
Bodyport Cardiac Scale + Congestion Index platform
Founded
2015
Headquarters
120 2nd Street, 2nd Floor, San Francisco, CA 94105, United States
Team size
10-20
Work style
Onsite
Industry
Hospitals and Health Care
Sub-industry
Digital therapeutics / remote cardiac monitoring
Offices
120 2nd Street, 2nd Floor, San Francisco, CA 94105, United States
Business model
B2B medical device + software platform
remote patient monitoring (RPM)
digital therapeutics
clinical SaaS / EHR-integrated care platform
Funding
Stage
Series A
Total raised
$15.8M
Latest round
Series A · Aug 2020
Latest amount
$11.2M
People & investors
Leadership
Founder, President & CTO
Founder & Chief Product Officer
Board Member; former CEO (2022-2025)
Chief Revenue Officer
Head of Data Science
Medical Director
Head of Customer and Product Operations
Chair, Board of Directors
Work & culture
Mission-driven and evidence-led, with an emphasis on clinical rigor, patient-centered design, and partnerships with health systems and researchers.
Work style
Onsite
Compensation
No public salary bands were found. Third-party salary estimates suggest average US pay around $116.9k per year, with an estimated range near $103k-$132k, but this is not an official company policy.
Benefits
401(k) / retirement benefits
medical, dental, and vision insurance
equity
generous PTO
paid parental leave
Product & market
Pricing
Enterprise / B2B commercial model with device + software + RPM billing support; public pricing not disclosed.
Differentiators
- —Measures fluid status and hemodynamic biomarkers from a simple home scale step, not a wearable or implant
- —FDA-cleared noninvasive heart-failure monitoring platform
- —Congestion Index detected 70% of heart-failure events in published studies, ahead of weight-only monitoring
- —Combines device, clinical portal, patient app, API integrations, and compliance workflows
- —Aims to reduce false alerts and support earlier intervention
Technology
cellular-connected device
web-based clinical dashboard
patient app
API-based EHR integration
RPM billing support
HIPAA-compliant workflows
SOC 2-certified system
proprietary Congestion Index algorithm
hemodynamic biomarker sensing through the feet
Customers
Geisinger
Brigham and Women’s Hospital
health systems
cardiology / heart-failure programs
pharmaceutical and medtech partners
Competitors
Abbott CardioMEMS
Endotronix Cordella
AliveCor
iRhythm
Eko
Philips
Omron
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
854
Traffic estimate as of Jul 2026
Latest news
PR Newswire · Sep 2024
Journal of Cardiac Failure publication reported that Bodyport’s Congestion Index predicted heart failure events at twice the rate of weight-only monitoring, with an average lead time of 14 days and 38% fewer false alerts.
PR Newswire · Mar 2024
Late-breaking THT 2024 results from SCALE-HF 1 said Bodyport detected twice as many heart-failure events as weight-based monitoring while generating fewer alerts.
PR Newswire · Aug 2023
Bodyport and Geisinger announced a 12-month pilot using the FDA-cleared cardiac scale and Fluid Alerts for about 200 adult heart-failure patients.
Bodyport · Aug 2022
Bodyport announced FDA 510(k) clearance for the Cardiac Scale, a noninvasive biomarker platform for heart function and fluid-status monitoring.
Jobs and careers at Bodyport
0 jobs at Bodyport
No open positions
Check back later for new openings